HBP Share Price

Open 0.89 Change Price %
High 0.90 1 Day 0.09 11.11
Low 0.89 1 Week 0.01 1.12
Close 0.90 1 Month 0.00 0.00
Volume 1800 1 Year -0.80 -47.06
52 Week High 1.79
52 Week Low 0.70
HBP Important Levels
Resistance 2 0.91
Resistance 1 0.91
Pivot 0.90
Support 1 0.89
Support 2 0.89
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
BBD-B 2.23 -5.91%
TBE 0.03 0.00%
SC 60.83 -0.44%
PRE 0.64 0.00%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
PLS 3.60 30.43%
PLS 3.60 30.43%
PWC 0.10 25.00%
PWC 0.10 25.00%
GEN 0.11 22.22%
GEN 0.11 22.22%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
BNG 0.10 -16.67%
BNG 0.10 -16.67%
AAB 0.14 -12.50%
AAB 0.14 -12.50%
TPX-A 101.00 -10.61%
CTU-A 0.19 -9.52%
BLU 0.38 -7.32%
DEJ 0.14 -6.67%
DEJ 0.14 -6.67%
More..

Helix BioPharma Corp (TSE: HBP)

HBP Technical Analysis 4
As on 22nd Sep 2017 HBP Share Price closed @ 0.90 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.50 & Sell for SHORT-TERM with Stoploss of 0.93 we also expect STOCK to react on Following IMPORTANT LEVELS.
HBP Target for September
1st Target up-side 0.95
2nd Target up-side 0.98
3rd Target up-side 1.02
1st Target down-side 0.85
2nd Target down-side 0.82
3rd Target down-side 0.78
HBP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.helixbiopharma.com
HBP Address
HBP
305 Industrial Parkway South
Unit 3
Aurora, ON L4G 6X7
Canada
Phone: 905-841-2300
Fax: 905-841-2244
HBP Latest News
Interactive Technical Analysis Chart Helix BioPharma Corp ( HBP TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Helix BioPharma Corp
HBP Business Profile
Helix BioPharma Corp., a biopharmaceutical company, develops drugs for the prevention and treatment of cancer based on its proprietary technologies. The company focuses on the development of L-DOS47 that is in phase I/II clinical trial for the treatment of inoperable, locally advanced, and recurrent or metastatic non-small cell lung cancer; and Topical Interferon Alpha-2b, which has completed phase II study for the treatment of low-grade cervical lesions and ano-genital warts caused by human papilloma virus infections. It also offers DOS47, a patented oncology platform technology that derives a therapeutic pharmacological effect by acting upon a naturally occurring substance in the body. Helix BioPharma Corp. is based in Aurora, Canada.